Koschmieder, S
Mughal, T I
Hasselbalch, H C
Barosi, G
Valent, P
Kiladjian, J-J
Jeryczynski, G
Gisslinger, H
Jutzi, J S
Pahl, H L
Hehlmann, R
Maria Vannucchi, A
Cervantes, F
Silver, R T
Barbui, T
Article History
Received: 30 October 2015
Revised: 28 November 2015
Accepted: 1 December 2015
First Online: 8 February 2016
Competing interests
: Steffen Koschmieder: research funding (Novartis and Novartis Foundation); consultancy and advisory boards (Ariad, AOP, Baxalta, Bristol-Myers Squibb, CTI, Novartis, Pfizer, Sanofi); honoraria and travel grants (Ariad, Alexion, AOP, Baxalta, Bristol-Myers Squibb, Celgene, CTI, Novartis, Pfizer, Sanofi, Shire). Hans C Hasselbalch: research grant (Novartis). Peter Valent: honoraria (Novartis, Ariad, Pfizer und BMS); grant support (Novartis, Ariad); consultancy (Novartis Global PKC412 Trial). Heike Pahl: consultancy and advisory boards (AOP, Baxalta, Novartis, Shire). RĂ¼diger Hehlmann: research funding (BMS and Novartis). Alessandro Vannucchi: honoraria for advisory board and speaker fees (Novartis). Francisco Cervantes: advisory board (Novartis, AOP, and CTI-Baxter); speakers bureau (Novartis and CTI-Baxter).